Explore our ACCC 2020 Impact Report, the Oncology Issues, Vol.36 N.6, and our video podcast, CANCER BUZZ TV.
 

Share

    


Home / CANCER BUZZ Podcast / Podcast Detail

[PODCAST] Ep 44: The Promise of Bispecific Antibodies

November 24, 2020

Find the CANCER BUZZ podcast on Apple Podcasts, Spotify, or wherever you get your podcasts!

The redirection of T cells against tumors holds significant promise for the treatment of cancer. Two main approaches for T-cell redirection involve their genetic modification with chimeric antigen receptors (CAR) or the use of bispecific antibodies that can bind to two different antigens simultaneously.

On this episode of CANCER BUZZ, learn about these promising breakthroughs, the challenges facing their widespread use, and what your cancer team needs to know about the future of cancer treatment.

Guest: Firas El Chaer, MD, Assistant Professor of Medicine, Department of Hematology and Oncology, University of Virginia, Emily Couric Clinical Cancer Center

Related Content:

 

The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Association of Community Cancer Centers.